M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice

[1]  F. LaFerla,et al.  Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[2]  J. D. McGaugh,et al.  Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.

[3]  F. LaFerla,et al.  Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[5]  E. Godaux,et al.  A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. , 2004, The Journal of clinical investigation.

[6]  N. Hooper,et al.  ADAMs family members as amyloid precursor protein α‐secretases , 2003 .

[7]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[8]  V. Bigl,et al.  Amyloid precursor protein processing in vivo--insights from a chemically-induced constitutive overactivation of protein kinase C in Guinea pig brain. , 2003, Current medicinal chemistry.

[9]  James L McGaugh,et al.  Amygdala Modulation of Memory Consolidation: Interaction with Other Brain Systems , 2002, Neurobiology of Learning and Memory.

[10]  Alena Savonenko,et al.  Transgenic mouse models of neurodegenerative disease: Opportunities for therapeutic development , 2002, Current neurology and neuroscience reports.

[11]  E. Perry,et al.  Chronic nicotine treatment reduces beta-amyloidosis , 2002 .

[12]  E. Perry,et al.  Chronic nicotine treatment reduces β‐amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw) , 2002, Journal of neurochemistry.

[13]  D. Skovronsky,et al.  Neuronal localization of the TNFalpha converting enzyme (TACE) in brain tissue and its correlation to amyloid plaques. , 2001, Journal of neurobiology.

[14]  D. Westaway,et al.  New developments in animal models of Alzheimer’s disease , 2001, Current neurology and neuroscience reports.

[15]  R. Eglen,et al.  Therapeutic opportunities from muscarinic receptor research. , 2001, Trends in pharmacological sciences.

[16]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[18]  Xudong Huang,et al.  Metal Chelation as a Potential Therapy for Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[19]  T. Golde,et al.  A Novel γ-Secretase Assay Based on Detection of the Putative C-terminal Fragment-γ of Amyloid β Protein Precursor* , 2000, The Journal of Biological Chemistry.

[20]  E. Rybnikova,et al.  Metalloprotease-Disintegrin (ADAM) Genes Are Widely and Differentially Expressed in the Adult CNS , 2000, Molecular and Cellular Neuroscience.

[21]  T. Bliss,et al.  ERKI/II Regulation by the Muscarinic Acetylcholine Receptors in Neurons , 2000, The Journal of Neuroscience.

[22]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[23]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[24]  E. Kojro,et al.  Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  F. J. van der Staay,et al.  Animal models in the development of symptomatic and preventive drug therapies for Alzheimer's disease. , 1998, Annals of medicine.

[26]  Y. Kloog,et al.  Mitogen‐Activated Protein Kinase‐Dependent and Protein Kinase C‐Dependent Pathways Link the m1 Muscarinic Receptor to β‐Amyloid Precursor Protein Secretion , 1998 .

[27]  Joseph D. Buxbaum,et al.  Evidence That Tumor Necrosis Factor α Converting Enzyme Is Involved in Regulated α-Secretase Cleavage of the Alzheimer Amyloid Protein Precursor* , 1998, The Journal of Biological Chemistry.

[28]  A. Clerk,et al.  Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. , 1997, Cellular signalling.

[29]  J. Muir.  Acetylcholine, Aging, and Alzheimer's Disease , 1997, Pharmacology, Biochemistry and Behavior.

[30]  Nancy J. Woolf,et al.  The Critical Role of Cholinergic Basal Forebrain Neurons in Morphological Change and Memory Encoding: A Hypothesis , 1996, Neurobiology of Learning and Memory.

[31]  J. Buccafusco,et al.  m1–m5 Muscarinic Receptor Distribution in Rat CNS by RT‐PCR and HPLC , 1994, Journal of neurochemistry.

[32]  J. Growdon,et al.  Receptor‐coupled Amyloid Precursor Protein Processing a , 1993, Annals of the New York Academy of Sciences.

[33]  P. Greengard,et al.  Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Growdon,et al.  Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. , 1992, Science.

[35]  B. Winblad,et al.  Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia , 1992, Journal of neuroscience research.

[36]  D. Price,et al.  Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[37]  E. Giacobini,et al.  Nicotinic acetylcholine receptor subtypes in human frontal cortex: Changes in Alzheimer's disease , 1990, Journal of neuroscience research.

[38]  Bengt Winblad,et al.  Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains , 1986, Neuroscience Letters.

[39]  H. Ladinsky,et al.  Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine , 1986, British journal of pharmacology.

[40]  D. Spencer,et al.  Direct autoradiographic determination of M1 and M2 muscarinic acetylcholine receptor distribution in the rat brain: Relation to cholinergic nuclei and projections , 1986, Brain Research.

[41]  J. Coyle,et al.  Nicotinic acetylcholine binding sites in Alzheimer's disease , 1986, Brain Research.

[42]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[43]  B. Ibach,et al.  Acetylcholinesterase inhibition in Alzheimer's Disease. , 2004, Current pharmaceutical design.

[44]  N. Hooper,et al.  ADAMs family members as amyloid precursor protein alpha-secretases. , 2003, Journal of neuroscience research.

[45]  T. Golde,et al.  A novel gamma -secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor. , 2001, The Journal of biological chemistry.

[46]  D. Holtzman,et al.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Lovestone,et al.  Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3β inhibition and in neurons , 2000, Journal of Neural Transmission.

[48]  J. Buxbaum,et al.  Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. , 1998, The Journal of biological chemistry.

[49]  Y. Kloog,et al.  Mitogen-activated protein kinase-dependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion. , 1998, Journal of neurochemistry.